A late-stage trial of an Impax Laboratories Inc. drug, designed to control involuntary muscle jerks experienced by Parkinson’s disease patients, will report early results in late August.
Assuming positive results from the Phase III trial of Impax’s IPX-066, Hayward-based Impax (NASDAQ: IPXL) said it would file a new drug application with the Food and Drug Administration in the fourth quarter.
No comments:
Post a Comment